Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression

Nawangsih, Eka Noneng; Kusmala, Yudith Yunia; Rakhmat, Iis Inayati; Handayani, Dewi Ratih; Juliastuti, Henny; Wibowo, Arief; Lim, Michael Anthonius; Pranata, Raymond

doi:10.1016/j.intimp.2021.107723

Cited by 19 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As previously mentioned, this drug is not recommended for the management of patients with COVID-19, but preliminary data from some meta-analyses have shown that colchicine can reduce mortality, although most of the studies included in the analyzes were observational. Therefore, clinical trials are required to corroborate these findings [41][42][43].…”

Section: Discussionmentioning

confidence: 99%

Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia

et al. 2022

View full text Add to dashboard Cite

The impact of COVID-19 prompted a race to find a treatment that would reduce its mortality. Most studies have not shown favorable results for many of these drugs, but they are still used. The aim as to determine the differences and similarities in the hospital pharmacological management of patients with COVID-19 according to sex, age group, and geographical region of Colombia, 2020–2021. Descriptive cross-sectional study was conducted on the prescription patterns of the medications given to patients diagnosed with COVID-19 treated in eight clinics in Colombia between 6 March 2020 and 31 May 2021. We performed a descriptive analysis of the sociodemographic, clinical, and pharmacological variables of the patients. A total of 8596 patients from 170 cities were identified, with a median age of 53.0 years and 53.3% of them men. A total of 24.3% required care in the intensive care unit, and 18.7% required invasive mechanical ventilation. The most commonly used drugs for the treatment of COVID-19 were systemic corticosteroids (63.6%), followed by colchicine (12.8%), azithromycin (8.9%), and ivermectin (6.4%). Corticosteroids, anticoagulants, colchicine, azithromycin, ivermectin, and hydroxychloroquine were prescribed more frequently in men, and their overall use increased with age. There were differences in prescriptions between geographic regions. The majority of patients were managed with medications included in the management guidelines. There were differences between sexes, age groups, and geographical regions.

show abstract

Section: Discussionmentioning

confidence: 99%

Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Con respecto al uso de Colchicina en pacientes hospitalizados con COVID-19, otros autores han descrito un menor deterioro clínico (Deftereos et al, 2020) y menor mortalidad (Manenti et al, 2021). Incluso, un metaanálisis que incluyó 8 estudios con un total de 5530 pacientes soporta el uso de Colchicina para disminuir la mortalidad (Nawangsih et al, 2021). Si bien en nuestro estudió no se reportaron muertes en los pacientes sometidos a esta terapéutica, sin importar la severidad de la enfermedad, estos resultados deben tomarse con cautela dado el tamaño de la muestra que se evaluó.…”

Section: Discussionunclassified

Inmunosupresión vs. Inmunorregulación en COVID-19

Durán-Méndez

Nieto-Ortega

Peón³

2022

ICBI

View full text Add to dashboard Cite

La COVID-19 tiene un espectro clínico variable, desde una infección asintomática hasta una enfermedad crítica con desenlace mortal. Se han propuesto múltiples terapias, algunas con efectos a nivel de la respuesta inmunológica. En este estudio evaluamos el uso de Tocilizumab, Colchicina y Baricitinib en pacientes hospitalizados con infección por SARS-CoV-2. Se examinaron los expedientes clínicos de 133 pacientes hospitalizados con COVID-19 en 3 hospitales. Inicialmente, ninguno de estos medicamentos mostró ser superior al grupo Control en disminuir la mortalidad. Sin embargo, se realizó un análisis estratificado evidenciando que Tocilizumab puede reducir la mortalidad hasta un 3.7% vs 28.12% (p=0.01). La estancia intrahospitalaria fue mayor en los pacientes que recibieron Baricitinib y Tocilizumab comparados con el Control (14.25±2.06 y 10.58±3.66 respectivamente vs 8.30±2.86). Finalmente, Tocilizumab fue el único fármaco que redujo la probabilidad de un aumento en el requerimiento de oxígeno suplementario (OR 0.3094, 0.95% IC [0.1031-0.9287]). La terapia inmunorreguladora muestra ser útil para el manejo de pacientes con COVID-19.

show abstract

“…Chiu et al included six studies (3 observational studies and 3 randomized trials) having included 5033 patients and reported mortality risk reduction with colchicine administration (OR 0.36; 95% CI: 0.17–0.76), but this survival benefit was no longer significant when analyzing only randomized trial data (OR 0.49; 95% CI: 0.20–1.24) [ 105 ]. More recent meta-analyses of COVID-19 studies have also reported benefits of colchicine administration on mortality [ 106 , 107 , 108 , 109 ]. Of note, Nawangsih et al demonstrated that colchicine’s survival benefit is more pronounced in younger adults yet, remains statistically important irrespective of diabetes and coronary artery disease history [ 108 ].…”

Section: Colchicine and Covid-19 Infectionmentioning

confidence: 99%

“…More recent meta-analyses of COVID-19 studies have also reported benefits of colchicine administration on mortality [ 106 , 107 , 108 , 109 ]. Of note, Nawangsih et al demonstrated that colchicine’s survival benefit is more pronounced in younger adults yet, remains statistically important irrespective of diabetes and coronary artery disease history [ 108 ]. The incorporation of RECOVERY trial findings in a meta-analysis conducted by Lien et al did not alter the afore-mentioned survival benefit among colchicine treated patients [ 109 ] (see also Table 3 ).…”

Section: Colchicine and Covid-19 Infectionmentioning

confidence: 99%

Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine

Vrachatis

Papathanasiou

Giotaki

et al. 2021

JCM

View full text Add to dashboard Cite

In 2020, SARS-COV-2 put health systems under unprecedented resource and manpower pressure leading to significant number of deaths. Expectedly, researchers sought to shed light on the pathophysiologic background of this novel disease (COVID-19) as well as to facilitate the design of effective therapeutic modalities. Indeed, early enough the pivotal role of inflammatory and thrombotic pathways in SARS-COV-2 infection has been illustrated. The purpose of this article is to briefly present the epidemiologic and clinical features of COVID-19, analyze the pathophysiologic importance of immunologic dysregulation and hypercoagulability in developing disease complications and finally to present an up-to-date systematic review of colchicine’s immunomodulating capacity in view of hindering coronavirus complications.

show abstract

Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression

Cited by 19 publications

References 25 publications

Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia

Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia

Inmunosupresión vs. Inmunorregulación en COVID-19

Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine

Contact Info

Product

Resources

About